Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show ...

Read here for an analysis of Tamarack's (TNEYF) debt reduction, rising reserves, and profitability versus peers—plus a 2029 ...

Splitero reports on strategies for managing post-holiday debt, comparing home equity and credit card options to reduce ...

The new program is validated in a set of clinical pedigrees demonstrating its practical accuracy and relevance to the field. Collectively, the data are compelling and support the major conclusions of ...